Subscribe
Sign in
Home
Archive
About
Latest
Top
Discussions
"LUNAR: Full Moon or Eclipse? An exploration into tumor treating fields in lung cancer"
This is the title of our new paper out in the Journal of Cancer Policy!
Apr 17
•
Timothée Olivier
10
Share this post
The Drug Development Letter
"LUNAR: Full Moon or Eclipse? An exploration into tumor treating fields in lung cancer"
Copy link
Facebook
Email
Notes
More
2
How to appraise the control arm in oncology trials, in 10 minutes!
From a recent virtual session I had the pleasure of giving at IOSI, Ticino, Switzerland.
Apr 11
•
Timothée Olivier
19
Share this post
The Drug Development Letter
How to appraise the control arm in oncology trials, in 10 minutes!
Copy link
Facebook
Email
Notes
More
10:03
March 2025
"Surrogate end points in oncology: the speed-uncertainty trade-off from the patients' perspective"
This is my new paper out in Nature Reviews Clinical Oncology
Mar 25
•
Vinay Prasad
25
Share this post
The Drug Development Letter
"Surrogate end points in oncology: the speed-uncertainty trade-off from the patients' perspective"
Copy link
Facebook
Email
Notes
More
The 19th St Gallen Breast Oncology Conference begins on 12 March 2025 : "Should we combine adjuvant drugs that were tested in isolation in…
Our paper with Vinay Prasad is now published in the Journal of Cancer Policy – and it couldn’t be more timely!
Mar 9
•
Timothée Olivier
10
Share this post
The Drug Development Letter
The 19th St Gallen Breast Oncology Conference begins on 12 March 2025 : "Should we combine adjuvant drugs that were tested in isolation in phase 3 trials?"
Copy link
Facebook
Email
Notes
More
1
The ‘Duck Test’ for Huey, Dewey and Louie: the legal case on CDK4/6 inhibitors
Me-too drugs (drugs with the same mode of action for the same indication) are generally beneficial to society as they provide variation, choice and…
Mar 6
•
Sahar van Waalwijk
and
Hans Westgeest
22
Share this post
The Drug Development Letter
The ‘Duck Test’ for Huey, Dewey and Louie: the legal case on CDK4/6 inhibitors
Copy link
Facebook
Email
Notes
More
CDK4/6 Inhibitors and Novel Adjuvant Therapies: Using Statistics to Inform Shared Decision-Making
Here is the talk I gave on March 3rd 2025 at the CRUK Cambridge Institute. Thanks again to Dr. Henno Martin and the team for the invitation and the…
Mar 4
•
Timothée Olivier
14
Share this post
The Drug Development Letter
CDK4/6 Inhibitors and Novel Adjuvant Therapies: Using Statistics to Inform Shared Decision-Making
Copy link
Facebook
Email
Notes
More
5
1:01:48
February 2025
Vaccine Safety Research: Too Much Confounding and Spin.
In a systematic review, we found that authors of vaccine safety observational studies conceded residual confounding in about 75% of the studies…
Feb 25
•
Mariana B. Caiado Ferreira
24
Share this post
The Drug Development Letter
Vaccine Safety Research: Too Much Confounding and Spin.
Copy link
Facebook
Email
Notes
More
1
The CABINET study
100% NIH funded; 100% placebo controlled
Feb 21
•
Vinay Prasad
27
Share this post
The Drug Development Letter
The CABINET study
Copy link
Facebook
Email
Notes
More
3
19:17
Excessive Drug Price Leads to Hefty Fine for Company in the Netherlands
Why was a company fined €17 million for excessive pricing?
Feb 19
•
Sahar van Waalwijk
21
Share this post
The Drug Development Letter
Excessive Drug Price Leads to Hefty Fine for Company in the Netherlands
Copy link
Facebook
Email
Notes
More
1
Did pembrolizumab improve survival in patients with locally advanced cervical cancer due to poor access to post-protocol care?
We recently published our analysis in the journal Cancer, explaining why we believe an trial testing pembrolizumab in this setting – KEYNOTE-A18 …
Feb 9
•
Bart Penninx
,
Michael Samson
, and
John-John Schnog
14
Share this post
The Drug Development Letter
Did pembrolizumab improve survival in patients with locally advanced cervical cancer due to poor access to post-protocol care?
Copy link
Facebook
Email
Notes
More
4
Home-Grown CAR-T Cells: A Blessing or a Threat?
Biotech's pushback against the development of academic CAR-T cell therapy in the Netherlands.
Feb 5
•
Sahar van Waalwijk
20
Share this post
The Drug Development Letter
Home-Grown CAR-T Cells: A Blessing or a Threat?
Copy link
Facebook
Email
Notes
More
1
January 2025
"The landscape of checkpoint inhibitors in oncology" – part 2! Expanding Approvals, Eligibility, and Response
How many patients are eligible for and respond to checkpoint inhibitors? Here is our eagerly awaited updated analysis, now also including the regulatory…
Jan 30
•
Alyson Haslam
14
Share this post
The Drug Development Letter
"The landscape of checkpoint inhibitors in oncology" – part 2! Expanding Approvals, Eligibility, and Response
Copy link
Facebook
Email
Notes
More
1
Share
Copy link
Facebook
Email
Notes
More
This site requires JavaScript to run correctly. Please
turn on JavaScript
or unblock scripts